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Background: Oral cancer is a common cancer and a major health problem in the Indian subcontinent. At our
laboratory Mcl-1, an anti-apoptotic member of the Bcl-2 family has been demonstrated to be overexpressed in oral
cancers and to predict outcome in oral cancer patients treated with definitive radiotherapy. To study the role of
Mcl-1 isoforms in radiation response of oral squamous carcinoma cells (OSCC), we investigated in the present study,
the association of Mcl-1 isoform expression with radiosensitivity of OSCC, using siRNA strategy.
Methods: The time course expression of Mcl-1 splice variants (Mcl-1L, Mcl-1S & Mcl-1ES) was studied by RT-PCR,
western blotting & immunofluorescence, post-irradiation in oral cell lines [immortalized FBM (radiosensitive) and
tongue cancer AW8507 & AW13516 (radioresistant)]of relatively differing radiosensitivities. The effect of Mcl-1L
knockdown alone or in combination with ionizing radiation (IR) on cell proliferation, apoptosis & clonogenic
survival, was investigated in AW8507 & AW13516 cells. Further the expression of Mcl-1L protein was assessed in
radioresistant sublines generated by fractionated ionizing radiation (FIR).
Results: Three to six fold higher expression of anti-apoptotic Mcl-1L versus pro-apoptotic Mcl-1S was observed at
mRNA & protein levels in all cell lines, post-irradiation. Sustained high levels of Mcl-1L, downregulation of pro-
apoptotic Bax & Bak and a significant (P< 0.05) reduction in apoptosis was observed in the more radioresistant
AW8507, AW13516 versus FBM cells, post-IR. The ratios of anti to pro-apoptotic proteins were high in AW8507 as
compared to FBM. Treatment with Mcl-1L siRNA alone or in combination with IR significantly (P< 0.01) increased
apoptosis viz. 17.3% (IR), 25.3% (siRNA) and 46.3% (IR plus siRNA) and upregulated pro-apoptotic Bax levels in
AW8507 cells. Combination of siRNA & IR treatment significantly (P< 0.05) reduced cell proliferation and clonogenic
survival of radioresistant AW8507 & AW13516 cells, suggesting a synergistic effect of the Mcl-1L siRNA with IR on
radiosensitivity. Interestingly, during the development of radioresistant sublines using FIR, high expression of Mcl-1L
was observed.
Conclusion: Our studies suggest that Mcl-1L isoform has an important role in the survival and radioresistance of
OSCC and may be a promising therapeutic target in oral cancers.Introduction
Squamous cell carcinoma of the oral cavity (OSCC) is
the most prevalent cancer in males of the Indian sub-
continent and is predominantly associated with the
tobacco-chewing habit [1]. Radiotherapy is an important
treatment modality in oral cancer aiding in tumor size
reduction and preservation of oral function [2]. Despite
advances in radiotherapy techniques, OSCC patients* Correspondence: tteni@actrec.gov.in
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reproduction in any medium, provided the orfrequently develop loco-regional recurrence resulting in
5-year survival rates that have remained unchanged for
past few decades [3]. Hence for successful radiotherapy,
it is crucial to understand the mechanisms involved in
the development of radiation resistance in tumor cells.
Anti-apoptotic members of the Bcl-2 family are the
key regulators of cellular apoptosis and their over ex-
pression has been shown to be associated with radio-
resistance [4,5]. Mcl-1 (Myeloid cell leukemia-1), an
anti-apoptotic member of the Bcl-2 gene family, is es-
sential for development, differentiation, and proliferational Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Palve and Teni Radiation Oncology 2012, 7:135 Page 2 of 11
http://www.ro-journal.com/content/7/1/135[6]. The overexpression of Mcl-1 has also been reported
in a variety of hematopoietic, lymphoid and solid tumors
[7-9]. Our earlier studies demonstrate the overexpres-
sion of anti-apoptotic Mcl-1 transcripts & protein in oral
tumors and cell lines [10]. Further, we have also demon-
strated Mcl-1 to be a prognostic factor in oral cancer
patients treated with definitive radiotherapy [11]. Earlier,
Mcl-1 has been shown to contribute in resistance of
cancer cells to chemotherapeutic agents, however
reports on its role in radiation induced apoptosis and
radioresistance are rare [12,13]. Further, the situation is
complex due to the existence of distinct Mcl-1 isoforms
having contrasting functions (anti-apoptotic Mcl-1L,
pro-apoptotic Mcl-1S & Mcl-1ES)[14]. Earlier studies
from our lab have demonstrated a five to ten fold higher
expression of anti-apoptotic Mcl-1L transcript, versus
the pro-apoptotic Mcl-1S in oral tumors [10]. Therefore,
in the present study we wanted to investigate the associ-
ation of Mcl-1 isoforms with radioresistance of oral can-
cer cells using siRNA strategy. To the best of our
knowledge, no reports are available on the role of Mcl-1
splice variants in radiation response of OSCC.
The present study was undertaken to compare the
time course profile of Mcl-1 splice variants and other
Bcl-2 family members, post-radiation (IR) treatment in
oral cell lines of differing radiosensitivities. Further, the
effect of Mcl-1L knockdown alone or in combination
with IR on cell proliferation, apoptosis and radiosensitiv-
ity of oral cells was investigated.Materials and methods
Cell culture
Established AW8507 & AW13516 [10,15] & FBM (fetal
buccal mucosa derived immortalized cell line) [16] were
selected for the study due to their differing radiosensitiv-
ities. The cell lines were cultured in IMDM supplemen-
ted with 10% FBS (Gibco, US), 100 units/ml penicillin,
100 μg/ml streptomycin, 2mM L-glutamine and kera-
tinocyte growth supplements only for FBM (Sigma,
USA), in 5% CO2 at 37°C.Clonogenic Assay
Exponentially growing oral cells were harvested, counted
and replated in duplicates. After 24 hrs, the cells were
treated with different doses of IR (1, 2, 4, 6, 8, 10 Gy)
using 60Co-γ radiator along with an untreated control.
Cells were then incubated up to 14 days to form col-
onies which were fixed and stained with a mixture of
glutaraldehyde (6.0% v/v) and crystal violet (0.5% w/v)
and colonies (≥50 cells) were counted using a micro-
scope. The percent plating efficiency and fraction surviving
a given radiation dose were calculated based on the sur-
vival of non-irradiated cells as described earlier [17].Radiation Treatment
After 48 hrs of plating exponentially growing cells
(6× 103 cells) were treated with IR (D0 dose) using
60Co-γ
radiator as described earlier [13]. Cells were incubated
upto different time points, harvested and stored in -80°C
until use.
RNA isolation
Cell pellets were placed in TRI reagent (Sigma, USA)
and total cellular RNA was isolated according to the
manufacturer’s protocol. The RNA was dissolved in
DEPC-treated water and contaminating DNA was
removed by DNaseI treatment (Sigma, USA). RNA in-
tegrity was analyzed by electrophoresis and samples
were preserved at −80°C until analysis, as described
earlier [10].
Reverse transcriptase-polymerase chain reaction
cDNA was synthesized with 2 μg total RNA, using a First
Strand cDNA synthesis kit (MBI Fermentas, Canada)
according to the manufacturer’s instructions. The effi-
ciency of cDNA synthesis and equal loading were assessed
by ß-actin PCR. Mcl-1 isoforms (Mcl-1L, Mcl-1S & Mcl-
1ES isoforms) were amplified by using primers (forward
5’ACGCGGTAATCGGACTCAACCT3’ and reverse 5’GC
AGCACATTCCTGATGCCACCT3’), as reported earlier
[10]. A separate PCR was performed to determine expres-
sion of Mcl-1ES isoform using forward (5’ACGCGGTA
ATCGGACTCAACCT3’) and reverse (5’GCAGCACATT
CCTGATGCCACCT3’) primers as shown in Additional
file 1. PCR products were resolved on 2% agarose gel con-
taining ethidium bromide and quantitated using Gel-doc
system (UVP, UK).
Western blotting
Cell lysates were resolved on 12% SDS-PAGE gels and
transferred onto PVDF membranes (Millipore, USA).
Membranes were blocked with 5% skimmed milk in TBS
for 2 hrs. Primary antibodies used were anti-Bax (1:150,
Abcam, USA), anti-Mcl-1 (1:1000), anti-Bclxl (1:1000)
and anti-ß-actin (1:2000) (Santa Cruz Biotechnology,
USA). Secondary antibodies used were Horseradish per-
oxidase conjugated IgG (1:5000) (Santa Cruz Biotechnol-
ogy, USA). Proteins were visualized with enhanced
chemiluminescence kit (GE Healthcare, US). Densitom-
etry analysis of developed X-ray film was performed
using ImageJ software (NIH, Bethesda, MD). β-actin was
used as loading control.
Apoptosis detection by flow cytometry
The Annexin V-FITC apoptosis detection kit (Santa
Cruz Biotechnology, CA) was used for the detection of
apoptotic cells in the three oral cell lines, as per the
manufacturer’s specifications. Briefly, cells were collected
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24 & 48 hrs) post-IR treatment. Cells were washed; 2μg
Annexin-V FITC & 10 μl PI were added, incubated in
the dark for 15 min and analyzed on a flow cytometer
(FACS Caliber, BD, USA).
Immunofluorescence staining
Cells were grown on glass cover slips and Mcl-1 stain-
ing was performed at different time points in both
FBM & AW8507, post-IR using an Alexa fluor-488 la-
beled secondary antibody (1:1000, Molecular Probes,
USA), as described earlier [10]. The AW8507 cells were
treated with siRNA (100nM) and/or exposed to IR as
described above. The nuclear condensation and apop-
tosis was analyzed by DAPI (Sigma-Aldrich, USA)
staining, cell counting and imaging was done by con-
focal microscope with LSM Image Browser 4.2 software
(Carl Zeiss).
Knockdown of Mcl-1L isoform
Knockdown was achieved using Mcl-1L specific siRNA
(sc-43912) along with a control siRNA (sc-37007) fromFigure 1 Radiosensitivity assessment and expression of Mcl-1 isoform
& AW13516 oral cell lines. Data given as percentage survival of untreated c
colony formation experiments. (b) Expression of Mcl-1 isoforms in oral cell
oral cell lines (FBM, AW13516 & AW8507). A representative blot was shown
expression of Mcl-1 isoforms (Mcl-1L & Mcl-1S) at both mRNA & protein levSanta Cruz biotechnology, USA. The siRNA duplexes
were transfected using Lipofectamine-2000 (Invitrogen)
according to the manufacturer’s instructions. The
medium was changed after 16 hrs of transfection and 24
hrs post-transfection the cells were assessed for knock-
down by western blotting. The specific silencing of Mcl-1L
was confirmed in three independent experiments.
Trypan blue exclusion assay
Cells were seeded into 24-well plates at a density of
5 × 104 per well and treated with Mcl-1L siRNA and/or
IR as described above. Cells were trypsinized and trypan
blue staining was performed after 48 hrs of treatment.
The number of viable cells were counted and compared
to untreated control using a hemocytometer.
Acquired radioresistant sublines
Radioresistant sublines were generated by irradiating
AW8507 & AW13516 cells with a fractionated Ionizing
radiation (FIR) strategy as described earlier [18]. During
development of radioresistant cell lines, cells were col-
lected at different doses (Control, 8, 16, 24, 32, 40 Gy)s in oral cell lines. (a) Clonogenic cell survival assay of FBM, AW8507
ell cultures and represent the means (±SD) of three independent
lines. RT-PCR and western blot analysis of Mcl-1 isoforms in the three
for three independent experiments. Histogram indicates quantitative
el in oral cell lines.
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to determine Mcl-1L expression by western blotting.
Statistical analysis
Statistical analysis was performed by using a Student’s
t-test analysis. The difference between means was consid-
ered statistically significant when P< 0.05. The data is illu-
strated as mean± standard deviation of three independent
experiments.
Results
Analysis of clonogenic survival of oral cell lines
Radiosensitivity assessment of the three oral cell lines
(FBM, AW13516 & AW8507) used in the study was
determined by the clonogenic survival assay (Figure 1a).
The D0 values obtained from the surviving fractions of
FBM, AW13516 & AW8507 were 2.3, 5.1 & 5.4 Gy re-
spectively, indicating FBM to be most radiosensitive
among all three oral cell lines.
Expression of Mcl-1 splice variants in oral cell lines and
effect of irradiation
RT-PCR using a single primer which amplifies all three
isoforms of Mcl-1 showed predominant expression of
anti-apoptotic Mcl-1L and low levels of Mcl-1S but un-
detectable levels of Mcl-1ES in all three oral cell lines.
Separate RT-PCR of poorly expressed Mcl-1ES isoform
showed very low levels of Mcl-1ES as compared to Mcl-1L
& Mcl-1S in all the three oral cell lines (Additional file 1).
The more radioresistant AW8507 & AW13516 cells
showed high expression of Mcl-1L at both mRNA &
protein levels as compared to immortalized FBM cells
(Figure 1b). Post-IR, the time course expression profiles
of Mcl-1 isoforms in the three oral cell lines revealed in-
duction of Mcl-1L protein in all three cell lines. How-
ever, radiosensitive FBM exhibited a rapid and short
induction profile with a peak at 1.5 hrs which declined
by 48 hrs. While the more radioresistant AW8507
exhibited sustained high levels of Mcl-1L up to 48 hrs
with a peak observed at 1.5 hrs (Figure 2a). A similar
pattern was observed in AW13516 (data not shown). In
all cell lines, the expression of short Mcl-1S was ele-
vated at initial time points which later decreased up to
48 hrs while, the short pro-apoptotic Mcl-1ES isoform
levels remained unaltered (See Additional file 2).
Analysis of Bax, Bcl-xl & Bcl-2 protein expression
Interestingly, AW8507 cell line exhibited a rapid down-
regulation of pro-apoptotic Bax & Bak proteins, 2hrs
post-IR. In contrast the more radiosensitive FBM
showed a consistent increase in Bax & Bak levels, 2hrs
onwards (Figure 2b). Higher expression of Bcl-2 & Bcl-xl
protein was observed in AW8507 as compared to FBM.
The AW13516 cell line also showed similar results.Ratios of anti to pro-apoptotic members
It is noteworthy that, the more radioresistant AW8507
cell line exhibited higher ratios of anti to pro-apoptotic
proteins like Mcl-1L/Mcl-1S, Mcl-1L/Bax & Bcl-xl/Bax
as compared to that in FBM post-IR (Figure 3 a-f ). A
similar pattern was observed in AW13516 (data not
shown).
Effect of Mcl-1 expression on apoptosis
As compared to untreated control, post-IR up to 1 hr, a
uniform time-dependent increase in apoptotic popula-
tion was observed in all three oral cell lines. Notably, the
number of apoptotic cells in AW13516 & AW8507 sig-
nificantly (P < 0.05 at 24 hrs & P < 0.01 at 48 hrs)
decreased thereafter as compared to that of FBM viz.
from 17.5% to 9% at 24 hrs & 27% to 12% at 48 hrs of
post-IR (Figure 4a), coinciding with the high Mcl-1L/
Mcl-1S ratio (Figure 3b).
Localization of Mcl-1 protein
Immunofluorescence staining demonstrated that Mcl-1
protein was primarily localized in the cytosolic compart-
ment of untreated AW8507 & FBM cells. Interestingly
post-IR a substantial increase in Mcl-1 protein expres-
sion with peri-nuclear and nuclear localization at 4 hrs
was observed in AW8507 cells, whereas no significant
change in expression and localization was observed in
FBM (Figure 4b).
siRNA mediated downregulation of Mcl-1L
AW8507 cells exhibited specific downregulation of Mcl-
1L levels after transfection with 100nM Mcl-1L siRNA
without affecting the Mcl-1S levels (Figure 5a). The ef-
fect of Mcl-1L siRNA was maximal between 6 to 72 hrs
and the Mcl-1S levels were unaltered. Treatment with
siRNA and IR alone or in combination significantly
increased expression of pro-apoptotic Bax protein but
did not change Bak & Bcl-xl protein levels (Figure 5b).
Effect Mcl-1L downregulation on cell proliferation and
apoptosis
Trypan blue dye exclusion assay in AW13516 &
AW8507 revealed a significant (P < 0.05) decrease in via-
bility of cells treated with combination of siRNA plus IR
as compared to individual treatments. After 72 hrs, cell
viability was reduced to 67% (IR), 42% (siRNA) and 21%
(IR plus siRNA) respectively (Figure 6a&b). Thereby,
suggesting a synergistic effect of the combined treatment
on cell viability.
Immunofluroscence analysis of AW13516 & AW8507
demonstrated an increased nuclear condensation in cells
treated with combined Mcl-1L siRNA plus IR as com-
pared to IR or siRNA alone (Figure 6c). The percentage
of apoptotic cells in experimental control (EC), UC, IR,
Figure 2 Time course profile of Mcl-1 splice variants & apoptosis related proteins post-IR. (a) Expression of Mcl-1L, Mcl-1S transcripts and
proteins at different time points post-IR in FBM & AW8507. Post-IR cells were harvested at different time points, used for RT-PCR and Western
blotting. (b) Western blot illustrates expression of Bax, Bak, Bcl-xl & Bcl-2 proteins at different time points post-IR in oral cell lines, using β-actin as
loading control. A representative blot for three independent experiments is shown.
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(SD 0.5), 3.2% (SD 0.6), 17.3% (SD 0.5), 25.3% (SD 1.1)
and 46.3% (SD 0.6), respectively (Figure 6d). A similar
pattern was observed in AW13516. The difference in
percentage of apoptosis between IR alone and siRNA
plus IR treated cells was highly significant (P < 0.01) in
both the cell lines.
Effect of Mcl1L knockdown on clonogenic survival
The effect of Mcl-1L downregulation on long term cell
survival was examined by clonogenic assay in AW8507 &
AW13516 cells. Interestingly, a reduction in clonogenic
survival was observed after treatment of Mcl-1L siRNA
(100nM) and increasing doses of IR as compared to the
untreated control (Figure 7). The survival of AW8507
post-IR (0, 2, 4, 6 8 and 10Gy) was 78% (SD 2.1), 46%(SD 1.5), 32% (SD 2.3) and 14% (SD 1.8) and 6% (SD 1.9)
respectively. However, in presence of Mcl-1 siRNA the
survival was further reduced to 42% (SD 2.6), 23% (SD
1.7), 10% (SD 1.0), 4% (SD 2.1) and 2% (SD 1.7), respect-
ively (Figure 7a). Similar reduction in clonogenic survival
post Mcl-1L knockdown was observed in AW13516 cells
(Figure 7b). These observations therefore suggest a syn-
ergistic effect of the Mcl-1L siRNA with IR on
radiosensitivity.Expression of Mcl-1L in radioresistant sublines
To evaluate the association of Mcl-1L with radioresis-
tance, its expression was assessed by western blotting in
acquired radioresistant sublines of AW8507 & AW13516.
Figure 8 demonstrates the high Mcl-1L expression in
Figure 3 Ratios of anti to pro-apoptotic proteins; Mcl-1L/Mcl-1S (a-b), Mcl-1L/Bax (c-d) and Bcl-xl/Bax (e-f) in AW8507 & FBM cell lines.
The relative ratios of expression of proteins were obtained by densitometry of blots using ImageJ software (NIH, USA).
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ation as compared to parental untreated cells.
Discussion
In the present study, we demonstrate the effect of anti-
apoptotic Mcl-1L expression on radiosensitivity of oral
cancer cells. So far, limited information is available on
the role of Mcl-1 in radiation response of tumor cells.
To our knowledge, this is the first study to report a time
course expression of Mcl-1 isoforms post-IR and effectof Mcl-1L knockdown on radiosentitzation of oral can-
cer cell lines using siRNA strategy. Our studies demon-
strated an inverse correlation of Mcl-1 expression with
cellular apoptosis and a synergistic effect of Mcl-1L
knockdown along with IR on cell viability and clono-
genic survival thereby enhancing the radiosensitivity of
OSCC cells.
Various growth factors and cellular stresses like radi-
ation and cytotoxic agents are known to upregulate Mcl-
1 levels, thereby enhancing short term viability [19]. Our
Figure 4 Apoptosis induction and localization of Mcl-1 post-IR. (a) Percentage of apoptosis induction at different time points post-IR by
Annexin-V & PI staining analyzed by FACS. The flow cytometry data shown is representative of three independent experiments (*P< 0.05 &
**P< 0.01) (b) Immunofluorescence staining of Mcl-1 protein counterstained with DAPI (blue) shows peri-nuclear accumulation (inset) and
additional nuclear localization 4 hrs post-IR in AW8507 cells.
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Mcl-1L transcript and its association with poor disease free
survival in patients treated with definitive radiotherapy
[10,11]. In the present study, two tongue cancer (AW8507
& AW13516) and an immortalized oral (FBM) cell line
were used due to their differing radiosensitivities and
based on their D0 values, both AW8507 & AW13516 were
relatively more radioresistant than FBM. Therefore, toFigure 5 Western blot analysis of Mcl-1L knockdown. (a) Mcl-1L down
expression of Mcl-1S in AW8507 cells. The effect of Mcl-1L siRNA was analy
Bcl-xl proteins 24 hrs after transfection of AW8507 cells: [Experimental cont
(siRNA); irradiation (IR)]. A representative blot of three independently perforevaluate the association of Mcl-1L with radioresistance if
any, we evaluated the expression of Mcl-1 isoforms in
radioresistant AW8507 & AW13516 as compared to
radiosensitive FBM. Our studies revealed higher expres-
sion of Mcl-1L at both mRNA and protein level in rela-
tively more radioresistant AW8507 & AW13516 cell lines
versus FBM, indicating a possible association of anti-
apoptotic Mcl-1L splice variant with radioresistance.regulation using different concentrations of siRNA and unaltered
zed upto 96 hrs post transfection. (b) Expression of Mcl-1L, Bak, Bax &
rol without siRNA (EC); universal control siRNA (UC); Mcl-1L siRNA
med experiments is shown.
Figure 6 Microscopic analyses of cell proliferation and apoptosis after different treatment combinations. (a & b) After different treatment
combinations as described, cell growth of AW8507 & AW13516 cells were determined by counting cell numbers using Trypan blue dye exclusion
assay. Cell numbers are given in percent of untreated controls. Data are means ± SD of three independent experiments. (c & d) Apoptosis was
determined by DAPI staining, cells either untreated (Control) or treated with UC siRNA, Mcl-1L siRNA alone or in combination with IR. Apoptotic
cells were counted in different fields and shown as percent of apoptosis relative to control. Data are means ± SD of three independent
experiments. *indicates P< 0.05, ** P < 0.01.
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levels. Mcl-1 is known to be rapidly induced at the tran-
scriptional level and its mRNA has a short half life [19].
Mcl-1 is also regulated at the post-transcriptional level by
micro RNAs through a mir29 binding in the 3’UTR of
Mcl-1 mRNA [20]. Interestingly, the expression of mir29
was also found to be decreased in malignant cholangio-
cytes, favoring the increased levels of Mcl-1, whichFigure 7 Clonogenic survival analysis after Mcl-1L knockdown and/or
or treated with siRNA. After 24 hrs, cell culture dishes were treated with inc
indicated. Survival was assessed by performing clonogenic assay as describ
and represent the means (±SD) of three independent colony formation expindicates the possible reason for the observed high
levels of Mcl-1 mRNA in our cancer cells lines and also
responsible for its immediate degradation within few hours
post IR.
Mcl-1, a PEST domain containing protein is also
known to undergo ubiquitin dependent degradation by
the 26S proteosome and possesses a short half life of
one to 3 hrs is rapidly downregulated during apoptosisirradiation. (a & b) AW8507 & AW13516 cells were either untreated,
reasing doses of ionizing irradiation (0, 2, 4, 6 8 and 10 Gy) as
ed in Methods. Data are given as percentage survival of untreated cells
eriments.
Figure 8 Expression of Mcl-1L in radio resistant sublines. (a & b) AW8507 & AW13516 cells were treated with fractionated irradiation and
the radio resistant sublines were assayed for expression of Mcl-1L. β-actin blot from the same lysates serve as loading control.
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ligase specifically interact with the hydrophobic BH3
binding pocket of Mcl-1 and not with other anti-
apoptotic Bcl-2 family members [21] and are responsible
for the constitutive turnover of Mcl-1. Such ubiquitin
mediated degradation of Mcl-1 has been shown to be es-
sential for the initiation of apoptosis, following UV
damage [22]. Hence, it was interesting to study the time
course expression profile of Mcl-1 isoforms and other bcl-2
family members in the above cell lines post-IR. Also, Mcl-
1 protein is known to be phosphorylated by GSK-3β at
Ser159, located within the PEST domain, resulting in a
significant decrease in the protein half-life and leading to
initiation of apoptosis [23]. Such, alterations in the phos-
phorylation of Mcl-1 protein by GSK3 may also contribute
to the elevation of Mcl-1 levels.
Moreover, it is known that the short isoform Mcl-1S
only binds to Mcl-1L possibly neutralizing its anti-
apoptotic function [24]. No significant alterations in
levels of Mcl-1S & Mcl-1ESwere observed post IR, indi-
cating that the predominantly overexpressed Mcl-1L
isoform alone may contribute in generation of radiore-
sistance. Mcl-1L not only binds to Mcl-1S, but is also
known to heterodimerise with pro-apoptotic Bax & Bak
etc. preventing the release of cytochrome-c and subse-
quent apoptosis [25]. We observed a downregulation of
pro-apoptotic Bax & Bak proteins in AW8507 post-IR,
coinciding with decreased apoptosis, while in contrast,
FBM showed an increase in Bax & Bak protein levels.
We observed high expression of anti-apoptotic Bcl-xl
which has already been shown to be associated with
radiosensitization of colon cancer cells [26]. Thus, high
expression of Bcl-xl & Bcl-2, known radioresistant fac-
tors and Mcl-1L in more radioresistant AW8507 &
AW13516 than FBM may indicate their possible role in
radioresistance.
We assessed the ratios of Mcl-1L/Mcl-1S, Mcl-1L/Bax,
Bcl-xl/Bax, wherein radioresistant AW8507& AW13516
showed high ratios as compared to that in FBM indicating
predominance of anti-apoptosis which may contribute to
radioresistance. We are the first to elucidate the compara-
tive levels of Mcl-1 isoforms and their association with ra-
diation response in oral cell lines. The high and prolonged
expression of Mcl-1L observed in AW8507 & AW13516
could possibly be due to Mcl-1 protein stabilization viabinding with other proteins. Another reason could be its
enhanced half life due to S159/T163 phosphorylation
post-IR, reported to be crucial in nicotine mediated Mcl-1
activation and chemoresistance [27].
We observed a significant reduction in apoptosis post-
IR which coincided with the high levels of Mcl-1L, indi-
cating a possible association of Mcl-1L expression with
radiation response of AW8507 & AW3516 cells. The im-
munofluorescence staining of Mcl-1 indicated a peri-
nuclear accumulation & nuclear localization post IR in
more radioresistant AW8507 cell line. Such, peri-nuclear
accumulation of Mcl-1 has also been observed earlier in
polymorphonuclear leukocytes post-etoposide treatment
[28]. In AW8507, the observed nuclear and perinuclear
accumulation of Mcl-1 may possibly help in cell survival
to lower doses of DNA damaging agents. A similar regu-
latory role for Mcl-1 (snMcl-1), perhaps acting as an
adaptor protein in controlling the ATR-mediated
regulation of DNA damage checkpoint kinase Chk1
phosphorylation and activation has been reported, pla-
cing Mcl-1 at the interface of apoptosis and cell cycle
regulation [29]. Mcl-1 has been shown to regulate cell
cycle by binding to proteins like CDK1 & PCNA [30],
possibly explaining the observed nuclear localization
of Mcl-1. High expression of anti-apoptotic Mcl-1L
and Bcl-xl proteins and reduced pro-apoptotic pro-
teins like Bak & Bax together may possibly contribute
in lowering the sensitivity of AW8507 & AW3516 cells
to IR.
The downregulation of Mcl-1L alone was efficient in
induction of apoptosis in both AW8507 & AW13516
cells. Interestingly, the combination of Mcl-1L siRNA
plus IR induced significantly higher apoptosis as com-
pared to siRNA or IR-alone in both oral cell lines. Not-
ably, the expression of closely related Bcl-xl, a known
radioresistant factor was not altered. However, the ex-
pression of pro-apoptotic Bax protein correlated with
the increased apoptosis on Mcl-1L knockdown. This
overexpression of Bax, a downstream pro-apoptotic
member, may execute the intrinsic apoptotic pathway
resulting in increased cell death. To address the fact that
the induction of apoptosis may not necessarily lead to
long-term response to radiotherapy, we performed the
clonogenic assay which demonstrated that combination
of IR and Mcl-1L downregulation synergistically reduced
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alone. Our studies demonstrate that Mcl-1L downregu-
lation potentially enhanced radiosensitivity of AW8507
& AW13516 cells in vitro. Complex interactions occur
between Bcl-2 family proteins especially, Bak & Bax,
where Mcl-1 plays a crucial role in engaging and main-
taining pro-apoptotic Bak in an inactive state and accu-
mulates H2AX and ATM proteins to activate DNA
repair pathways, suggesting that elimination of cellular
Mcl-1 is crucial to initiate apoptotic pathway [31]. Over-
expression and nuclear accumulation of Mcl-1 in
AW8507 may occur due to a protein called IEX-1 which
has been shown to interact specifically and timely with
Mcl-1 controlling its accumulation and nuclear trans-
location in response to DNA damage and contribute in
the activation of DNA repair pathway by Chk1 activation
and G2 checkpoint arrest [32].
The high expression of Mcl-1L, in radioresistant sub-
lines developed by fractionated ionizing radiation pro-
vides a direct evidence for the role of Mcl-1L in
radioresistance of OSCC cells. Therefore, the combin-
ation of radiotherapy and Mcl-1L downregulation has
the potential to improve the response rate of treatment-
resistant oral cancer cells. Selective inhibitors like Oba-
toclax, which specifically overcome Mcl-1 mediated re-
sistance, is already in phase 2 clinical trials [33] and may
have important therapeutic implications, when used in
combination with radiotherapy in treatment of oral can-
cer patients.Conclusion
Our studies indicate the association of Mcl-1L isoform
expression with radioresistance by influencing apoptosis,
proliferation and clonogenic survival of OSCC. Thus,
Mcl-1L appears to be a promising molecular target for im-
proving outcome of radiotherapy in oral cancer patients.Additional files
Additional file 1: Figure S1. Indicating expression of Mcl-1ES isoform in
three oral cell lines done by separate RTPCR.
Additional file 2: Figure S2. Time course profile of Mcl-1ES splice
variant (done by separate PCR) along with another two (Mcl-1L & Mcl-1S
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Post-IR: Post Irradiation; FIR: Fractionated Ionizing Radiation; IR: Ionizing
Radiation; IMDM: Iscove's Modified Dulbecco's Media; FBS: Fetal bovine
serum; PBS: Phosphate-buffered saline; PVDF: Polyvinyldene fluoride; DAPI: 4'-
6-Diamidino-2-phenylindole; SD: Standard deviation; SDS-PAGE: Sodium
dodecyle sulfate polyacrylamide gel electrophoresis.
Competing interests
Both authors declare that they have no competing interests.Authors’ contributions
VP aided in study design, performed experimental procedures, analyzed the
data and drafted manuscript. TT designed the study and reviewed the
manuscript. All authors read and approved the final manuscript.
Received: 10 May 2012 Accepted: 19 July 2012
Published: 8 August 2012References
1. Tandle AT, Sanghvi V, Saranath D: Determination of p53 genotypes in oral
cancer patients from India. Br J Cancer 2001, 84:739–742.
2. Burri RJ, Lee NY: Concurrent chemotherapy and radiotherapy for head
and neck cancer. Expert Rev Anticancer Ther 2009, 9:293–302.
3. Mathew Iype E, Pandey M, Mathew A, Thomas G, Krishnan Nair M:
Squamous cell cancer of the buccal mucosa in young adults. Br J Oral
Maxillofac Surg 2004, 42:185–189.
4. Kyprianou N, King E, Bradbury D, Rhee J: bcl-2 over-expression delays
radiation-induced apoptosis without affecting the clonogenic survival of
human prostate cancer cells. Int J Cancer
1997, 70:341–348.
5. Wang ZB, Zhang Y, Liu YQ, Guo Y, Xu H, Dong B, Cui YF: Bcl-xL
overexpression restricts gamma-radiation-induced apoptosis. Cell Biol Int
2006, 30:15–20.
6. Craig R: MCL1 provides a window on the role of the BCL2 family in cell
proliferation, differentiation and tumorigenesis. Leukemia 2002, 16:444–454.
7. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S,
Bodingbauer M, Crevenna R, Monia BP, Peck-Radosavljevic M, Wacheck V:
Mcl-1 overexpression in hepatocellular carcinoma: a potential target for
antisense therapy. J Hepatol 2006, 44:151–157.
8. Derenne S, Monia B, Dean N, Taylor J, Rapp M, Harousseau J, Bataille R,
Amiot M: Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL
is an essential survival protein of human myeloma cells. Blood 2002,
100:194.
9. Cho-Vega JH, Rassidakis GZ, Admirand JH, Oyarzo M, Ramalingam P,
Paraguya A, McDonnell TJ, Amin HM, Medeiros LJ: MCL-1 expression in B-cell
non-Hodgkin's lymphomas. Hum Pathol 2004, 35:1095–1100.
10. Mallick S, Patil R, Gyanchandani R, Pawar S, Palve V, Kannan S, Pathak KA,
Choudhary M, Teni TR: Human oral cancers have altered expression of
Bcl-2 family members and increased expression of the anti-apoptotic
splice variant of Mcl-1. J Pathol 2009, 217:398–407.
11. Mallick S, Agarwal J, Kannan S, Pawar S, Kane S, Teni T: PCNA and anti-
apoptotic Mcl-1 proteins predict disease-free survival in oral cancer
patients treated with definitive radiotherapy. Oral Oncol 2010, 46:688–693.
12. Guoan X, Hanning W, Kaiyun C, Hao L: Adenovirus-mediated siRNA
targeting Mcl-1 gene increases radiosensitivity of pancreatic carcinoma
cells in vitro and in vivo. Surgery 2010, 147:553–561.
13. Skvara H, Thallinger C, Wacheck V, Monia BP, Pehamberger H, Jansen B,
Selzer E: Mcl-1 blocks radiation-induced apoptosis and inhibits
clonogenic cell death. Anticancer Res 2005, 25:2697–2703.
14. Kim JH, Sim SH, Ha HJ, Ko JJ, Lee K, Bae J: MCL-1ES, a novel variant of
MCL-1, associates with MCL-1L and induces mitochondrial cell death.
FEBS Lett 2009, 583:2758–2764.
15. Tatake RJ, Rajaram N, Damle RN, Balsara B, Bhisey AN, Gangal SG:
Establishment and characterization of four new squamous cell
carcinoma cell lines derived from oral tumors. J Cancer Res Clin Oncol
1990, 116:179–186.
16. Raul U, Sawant S, Dange P, Kalraiya R, Ingle A, Vaidya M: Implications of
cytokeratin 8/18 filament formation in stratified epithelial cells: induction
of transformed phenotype. Int J Cancer 2004, 111:662–668.
17. Franken N, Rodermond H, Stap J, Haveman J, van Bree C: Clonogenic assay
of cells in vitro. Nat Protoc 2006, 1:2315–2319.
18. Fukuda K, Sakakura C, Miyagawa K, Kuriu Y, Kin S, Nakase Y, Hagiwara A,
Mitsufuji S, Okazaki Y, Hayashizaki Y, Yamagishi H: Differential gene
expression profiles of radioresistant oesophageal cancer cell lines
established by continuous fractionated irradiation. Br J Cancer 2004,
91:1543–1550.
19. Opferman JT: Unraveling MCL-1 degradation. Cell Death Differ 2006,
13:1260–1262.
20. Mott JL, Kobayashi S, Bronk SF, Gores GJ: mir-29 regulates Mcl-1 protein
expression and apoptosis. Oncogene 2007, 26:6133–6140.
Palve and Teni Radiation Oncology 2012, 7:135 Page 11 of 11
http://www.ro-journal.com/content/7/1/13521. Warr MR, Acoca S, Liu Z, Germain M, Watson M, Blanchette M, Wing SS,
Shore GC: BH3-ligand regulates access of MCL-1 to its E3 ligase. FEBS Lett
2005, 579:5603–5608.
22. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X: Elimination
of Mcl-1 is required for the initiation of apoptosis following ultraviolet
irradiation. Genes Dev 2003, 17:1475.
23. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR: Glycogen
synthase kinase-3 regulates mitochondrial outer membrane
permeabilization and apoptosis by destabilization of MCL-1. Mol Cell
2006, 21:749–760.
24. Bae J, Leo CP, Hsu SY, Hsueh AJ: MCL-1S, a splicing variant of the
antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein
possessing only the BH3 domain. J Biol Chem 2000, 275:25255–25261.
25. Thomas LW, Lam C, Edwards SW: Mcl-1; the molecular regulation of
protein function. FEBS Lett 2010, 584:2981–2989.
26. Wacheck V, Selzer E, Gunsberg P, Lucas T, Meyer H, Thallinger C, Monia BP,
Jansen B: Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer
cells. Br J Cancer 2003, 89:1352–1357.
27. Zhao J, Xin M, Wang T, Zhang Y, Deng X: Nicotine enhances the
antiapoptotic function of Mcl-1 through phosphorylation. Mol Cancer Res
2009, 7:1954–1961.
28. Leuenroth SJ, Grutkoski PS, Ayala A, Simms HH: The loss of Mcl-1
expression in human polymorphonuclear leukocytes promotes
apoptosis. J Leukoc Biol 2000, 68:158.
29. Jamil S, Sobouti R, Hojabrpour P, Raj M, Kast J, Duronio V: A proteolytic
fragment of Mcl-1 exhibits nuclear localization and regulates cell growth
by interaction with Cdk1. Biochem J 2005, 387:659.
30. Yang-Yen HF: Mcl-1: a highly regulated cell death and survival controller.
J Biomed Sci 2006, 13:201–204.
31. Cuconati A, Mukherjee C, Perez D, White E: DNA damage response and
MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes
Dev 2003, 17:2922–2932.
32. Pawlikowska P, Leray I, de Laval B, Guihard S, Kumar R, Rosselli F, Porteu F:
ATM-dependent expression of IEX-1 controls nuclear accumulation of
Mcl-1 and the DNA damage response. Cell Death Differ 2010, 17:1739–1750.
33. Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W,
James L, Ginsberg MS, Juergens R: A phase II study of obatoclax mesylate, a
Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Amsterdam, Netherlands: Lung cancer; 2011:74–481.
doi:10.1186/1748-717X-7-135
Cite this article as: Palve and Teni: Association of anti-apoptotic Mcl-1L
isoform expression with radioresistance of oral squamous carcinoma
cells. Radiation Oncology 2012 7:135.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
